[2015-May-21] FDA approves Stiolto™* Respimat® as once-daily maintenance treatment for COPD

https://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/26_may_2015_copd.html

Stiolto_Respimat.cdx

Bernd Disse, Richard Reichl, Georg Speck, Werner Traunecker, Karl Ludwig Rominger, and Rudolf Hammer, Ba 679 BR, A novel long-acting anticholinergic bronchodilator, Life Sci., 1993, 52 (5-6), pp 537-544

http://dx.doi.org/10.1016/0024-3205(93)90312-Q

Bernd Disse, Georg A. Speck, Karl Ludwig Rominger, Theodore J. Witek Jr., and Rudolf Hammer, Tiotropium (SPIRIVA™): Mechanistical considerations and clinical profile in obstructive lung disease, Life Sci., 1999, 64 (6-7), pp 457-464

http://dx.doi.org/10.1016/S0024-3205(98)00588-8

Thierry Bouyssou, Christoph Hoenke, Klaus Rudolf, Philipp Lustenberger, Sabine Pestel, Peter Sieger, Ralf Lotz, Claudia Heine, Frank H. Büttner, Andreas Schnapp, and Ingo Konetzki, Discovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacy, Bioorg. Med. Chem. Lett., 2010, 20 (4), pp 1410–1414

http://dx.doi.org/10.1016/j.bmcl.2009.12.087

T. Bouyssou, P. Casarosa, E. Naline, S. Pestel, I. Konetzki, P. Devillier, and A. Schnapp, Pharmacological Characterization of Olodaterol, a Novel Inhaled β2-Adrenoceptor Agonist Exerting a 24-Hour-Long Duration of Action in Preclinical Models, J. Pharmacol. Exp. Ther., 2010, 334 (1), pp 53-62

http://dx.doi.org/10.1124/jpet.110.167007

Mario Cazzola, and Mathieu Molimard, The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD, Pulm. Pharmacol. Ther., 2010, 23 (4), pp 257–267

http://dx.doi.org/10.1016/j.pupt.2010.03.003

Mario Cazzola Luigino Calzetta and Maria Gabriella Matera, β2-adrenoceptor agonists: current and future direction, British J. Pharmacol., 2011, 163 (1), pp 4-17

http://dx.doi.org/10.1111/j.1476-5381.2011.01216.x

Yasser Mushtaq, The COPD pipeline, Nat. Rev. Drug Discov., 2014, 13 (4), pp 253–254

http://dx.doi.org/10.1038/nrd4254

Andrew C. Kruse, Brian K. Kobilka, Dinesh Gautam, Patrick M. Sexton, Arthur Christopoulos and Jürgen Wess, Muscarinic acetylcholine receptors: novel opportunities for drug development, Nat. Rev. Drug Discov., 2014, 13 (7), pp 549–560

http://dx.doi.org/10.1038/nrd4295

Paolo Montuschi and Giovanni Ciabattoni, Bronchodilating Drugs for Chronic Obstructive Pulmonary Disease: Current Status and Future Trends, J. Med. Chem., 2015, 58 (10), pp 4131–4164

http://dx.doi.org/10.1021/jm5013227

[2015-Apr-15] FDA approves Corlanor to treat heart failure

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm442978.htm

Corlanor.cdx

S.M. Gardiner, P.A. Kemp, J.E. March and T. Bennett, Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats, British J Pharmacol., 1995, 115 (4), pp 579-586

http://dx.doi.org/10.1111/j.1476-5381.1995.tb14971.x

Irina Savelieva and A. John Camm, If Inhibition with Ivabradine, Drug Saf., 2008, 31 (2), pp 95-107

http://dx.doi.org/10.2165/00002018-200831020-00001

Andrea Rognoni, Marzia Bertolazzi, Sergio Maccio and Giorgio Rognoni, Ivabradine: Cardiovascular Effects, Recent Pat. Cardiovasc. Drug Discov., 2009, 4 (1), pp 61-66

http://dx.doi.org/10.2174/157489009787260016#sthash.3Q3jPmHe.dpuf

[2015-Mar-06] FDA approves new antifungal drug Cresemba

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm437106.htm

Cresemba.cdx

Peter A. Warn, Andrew Sharp and David W. Denning, In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp., J. Antimicrob. Chemother., 2006, 57 (1), pp 135-138

http://dx.doi.org/10.1093/jac/dki399

Anne Schmitt-Hoffmann, Brigitte Roos, Jürgen Maares, Markus Heep, Jochen Spickerman,

Erhard Weidekamm, Tom Brown and Michael Roehrle, Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers, Antimicrob. Agents Chemother., 2006, 50 (1), pp 286-293

http://dx.doi.org/10.1128/AAC.50.1.286-293.2006

H. Seifert, U. Aurbach, D. Stefanik and O. Cornely, In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream Isolates, Antimicrob. Agents Chemother., 2007, 51 (5), pp 1818-1821

http://dx.doi.org/10.1128/AAC.01217-06

A. C. Pasqualotto and D. W. Denning, New and emerging treatments for fungal infections, J. Antimicrob. Chemother., 2008, 61 (suppl. 1), pp i19-i30

http:/dx.doi.org/10.1093/jac/dkm428

Corrado Girmenia, New generation azole antifungals in clinical investigation, Expert Opin. Investig. Drugs, 2009, 18 (9), pp 1279-1295

http://dx.doi.org/10.1517/13543780903176407

[2015-Feb-25] FDA approves new antibacterial drug Avycaz

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm435629.htm

Avycaz.cdx

Ludo Verbist and Jan Verhaegen, GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae, Antimicrob. Agents Chemother., 1980, 17 (5), pp 807-812

http://dx.doi.org/10.1128/AAC.17.5.807

Ken Coleman, Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors, Curr. Opin. Microbiol., 2011, 14 (5), pp 550-555

http://dx.doi.org/10.1016/j.mib.2011.07.026

Z. Aktaş, C. Kayacan and O. Oncul, In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae, Int. J. Antimicrob. Agents, 2012, 39 (1), pp 86-89

http://dx.doi.org/10.1016/j.ijantimicag.2011.09.012

George G. Zhanel, Christopher D. Lawson, Heather Adam, Frank Schweizer, Sheryl Zelenitsky, Philippe R. S. Lagacé-Wiens, Andrew Denisuik, Ethan Rubinstein, Alfred S. Gin, Daryl J. Hoban, Joseph P. Lynch 3rd and James A. Karlowsky, Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination, Drugs, 2013, 73 (2), pp 159-177

http://dx.doi.org//10.1007/s40265-013-0013-7

[2015-Feb-23] FDA approves Farydak for treatment of multiple myeloma

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm435296.htm

Farydak.cdx

M. Cecilia Crisanti, Africa F. Wallace, Veena Kapoor, Fabian Vandermeers, Melissa L. Dowling, Luana P. Pereira, Kara Coleman, Barbara G. Campling, Zvi G. Fridlender, Gary D. Kao and Steven M. Albelda, The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer, Mol. Cancer Ther., 2009, 8 (8), pp 2221-2231

http://dx.doi.org/10.1158/1535-7163.MCT-09-0138

Jessica E. Bolden, Melissa J. Peart and Ricky W. Johnstone, Anticancer activities of histone deacetylase inhibitors, Nat. Rev. Drug Discov., 2006, 5 (9), pp 769-784

http://dx.doi.org/10.1038/nrd2133

[2015-Jan-29] HIV/AIDS Update - Prezcobix tablet containing 800 mg of darunavir and 150 mg of cobicistat approval

http://content.govdelivery.com/accounts/USFDA/bulletins/ed4466

Prezcobix.cdx

Arun K Ghosh, John F Kincaid, Wonhwa Cho, D.Eric Walters, K Krishnan, Khaja Azhar Hussain, Yumee Koo, Hanna Cho, Clare Rudall, Louis Holland and Jim Buthod, Potent HIV protease inhibitors incorporating high-affinity P2-ligands and (R)-(hydroxyethylamino)sulfonamide isostere, Bioorg. Med. Chem. Lett., 1998, 8 (6), pp 687-690

http://dx.doi.org/10.1016/S0960-894X(98)00098-5

Sandra De Meyer, Hilde Azijn, Dominique Surleraux, Dirk Jochmans, Abdellah Tahri, Rudi Pauwels, Piet Wigerinck and Marie-Pierre de Béthune, TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates, Antimicrob. Agents Chemother., 2005, 49 (6), pp 2314-2321

http://dx.doi.org/10.1128/AAC.49.6.2314-2321.2005

Bonaventura Clotet, Nicholas Bellos,Jean-Michel Molina, David Cooper, Jean-Christophe Goff ard, Adriano Lazzarin, Andrej Wöhrmann, Christine Katlama, Timothy Wilkin, Richard Haubrich, Calvin Cohen, Charles Farthing, Dushyantha Jayaweera, Martin Markowitz, Peter Ruane, Sabrina Spinosa-Guzman, Eric Lefebvre,on behalf of the POWER 1 and 2 study groups, Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials, Lancet, 2007, 369 (9568), pp 1169-1178

http://dx.doi.org/10.1016/S0140-6736(07)60497-8

Lianhong Xu, Hongtao Liu, Bernard P. Murray, Christian Callebaut, Melody S. Lee, Allen Hong, Robert G. Strickley, Luong K. Tsai, Kirsten M. Stray, Yujin Wang, Gerry R. Rhodes and Manoj C. Desai, Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer, ACS Med. Chem. Lett., 2010, 1 (5), pp 209–213

http://dx.doi.org/10.1021/ml1000257

Eve-Irene Lepist, Truc K. Phan, Anupma Roy, Leah Tong, Kelly MacLennan, Bernard Murray and Adrian S. Ray, Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, In Vitro, Antimicrob. Agents Chemother., 2012, 56 (10), pp 5409-5413

http://dx.doi.org/10.1128/AAC.01089-12

[2015-Jan-29] HIV/AIDS Update - Approval of Evotaz, containing 300 mg of atazanavir and 150 mg of cobicistat

http://content.govdelivery.com/accounts/USFDA/bulletins/ed4095

Evotaz.cdx

Brett S. Robinson, Keith A. Riccardi, Yi-fei Gong, Qi Guo, David A. Stock, Wade S. Blair, Brian J. Terry, Carol A. Deminie, Fred Djang, Richard J. Colonno, and Pin-fang Lin, BMS-232632, a Highly Potent Human Immunodeficiency Virus Protease Inhibitor That Can Be Used in Combination with Other Available Antiretroviral Agents, Antimicrob. Agents Chemother., 2000, 44 (8), pp 2093-2099

http://dx.doi.org/10.1128/AAC.44.8.2093-2099.2000

Katherine F. Croom, Sohita Dhillon, and Susan J. Keam, Atazanavir, Drugs, 2009, 69 (8), pp 1107-1140

http://dx.doi.org/10.2165/00003495-200969080-00009

Lianhong Xu, Hongtao Liu, Bernard P. Murray, Christian Callebaut, Melody S. Lee, Allen Hong, Robert G. Strickley, Luong K. Tsai, Kirsten M. Stray, Yujin Wang, Gerry R. Rhodes and Manoj C. Desai, Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer, ACS Med. Chem. Lett., 2010, 1 (5), pp 209–213

http://dx.doi.org/10.1021/ml1000257

Eve-Irene Lepist, Truc K. Phan, Anupma Roy, Leah Tong, Kelly MacLennan, Bernard Murray and Adrian S. Ray, Cobicistat Boosts the Intestinal Absorption of Transport Substrates, Including HIV Protease Inhibitors and GS-7340, In Vitro, Antimicrob. Agents Chemother., 2012, 56 (10), pp 5409-5413

http://dx.doi.org/10.1128/AAC.01089-12

[2015-Feb-13] FDA approves Lenvima for a type of thyroid cancer

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm434288.htm

Lenvima.cdx

Junji Matsui, Yasuhiro Funahashi, Toshimitsu Uenaka, Tatsuo Watanabe, Akihiko Tsuruoka and Makoto Asada, Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase, Clin. Cancer Res., 2008, 14 (17), pp 5459-5465

http://dx.doi.org/10.1158/1078-0432.CCR-07-5270

Haizhen Zhong and J. Phillip Bowen, Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways, Curr. Top. Med. Chem., 2011, 11 (12), pp 1571-1590

http://dx.doi.org/10.2174/156802611795860924

[2015-Feb-03] FDA approves Ibrance for postmenopausal women with advanced breast cancer

http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm432871.htm

ibrance.cdx

David W. Fry, Patricia J. Harvey, Paul R. Keller, William L. Elliott, MaryAnne Meade, Erin Trachet, Mudher Albassam, XianXian Zheng, Wilbur R. Leopold, Nancy K. Pryer and Peter L. Toogood, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts, Mol. Cancer Ther., 2004, 3 (11), pp 1427-1437

http://mct.aacrjournals.org/content/3/11/1427.abstract

Peter L. Toogood, Patricia J. Harvey, Joseph T. Repine, Derek J. Sheehan, Scott N. VanderWel, Hairong Zhou, Paul R. Keller, Dennis J. McNamara, Debra Sherry, Tong Zhu, Joanne Brodfuehrer, Chung Choi, Mark R. Barvian, and David W. Fry, Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6, J. Med. Chem., 2005, 48 (7), pp 2388–2406

http://dx.doi.org/10.1021/jm049354h

Michal Marzec, Monika Kasprzycka, Raymond Lai, Andrew B. Gladden, Pawel Wlodarski, Ewa Tomczak, Peter Nowell, Samuel E. DePrimo, Seth Sadis, Stephen Eck, Stephen J. Schuster, J. Alan Diehl, and Mariusz A. Wasik, Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity, Blood, 2006, 108 (5), pp 1744-1750

http://dx.doi.org/10.1182/blood-2006-04-016634

Raya Saab, Jennifer L. Bills, Alexander P. Miceli, Colleen M. Anderson, Joseph D. Khoury, David W. Fry, Fariba Navid, Peter J. Houghton and Stephen X. Skapek, Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells, Mol. Cancer Ther., 2006, 5 (5), pp 1299-1308

http://dx.doi.org/10.1158/1535-7163.MCT-05-0383

Richard S. Finn, Judy Dering, Dylan Conklin, Ondrej Kalous, David J. Cohen, Amrita J. Desai, Charles Ginther, Mohammad Atefi, Isan Chen, Camilla Fowst, Gerret Los and Dennis J. Slamon, PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro, Breast Cancer Res., 2009, 11 (5), R77

http://dx.doi.org/10.1186/bcr2419

[2015-Jan-30] FDA approves Glyxambi for adults with type 2 diabetes

http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2015/2-2-2015-us-fda-approves-first-in-class-glyxambi-empagliflozin-linagliptin-tablets-adults-type-2-diabetes.html

Glyxambi.cdx

R. Grempler, L. Thomas, M. Eckhardt, F. Himmelsbach, A. Sauer, D. E. Sharp, R. A. Bakker, M. Mark, T. Klein and P. Eickelmann, Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors, Diabetes Obes. Metab., 2012, 14 (1), pp 83-90

http://dx.doi.org/10.1111/j.1463-1326.2011.01517.x

Matthias Eckhardt, Elke Langkopf, Michael Mark, Moh Tadayyon, Leo Thomas, Herbert Nar, Waldemar Pfrengle, Brian Guth, Ralf Lotz, Peter Sieger, Holger Fuchs and Frank Himmelsbach, 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes, J. Med. Chem., 2007, 50 (26), pp 6450–6453

http://dx.doi.org/10.1021/jm701280z